Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 384

1.

Altered expression of fucosylation pathway genes is associated with poor prognosis and tumor metastasis in non‑small cell lung cancer.

Park S, Lim JM, Chun JN, Lee S, Kim TM, Kim DW, Kim SY, Bae DJ, Bae SM, So I, Kim HG, Choi JY, Jeon JH.

Int J Oncol. 2020 Feb;56(2):559-567. doi: 10.3892/ijo.2019.4953. Epub 2019 Dec 24.

PMID:
31894325
2.

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies.

Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, Kao S, Miller WH Jr, Delord JP, Gao B, Planchard D, Gottfried M, Zer A, Jalal SI, Penel N, Mehnert JM, Matos I, Bennouna J, Kim DW, Xu L, Krishnan S, Norwood K, Ott PA.

J Thorac Oncol. 2019 Dec 20. pii: S1556-0864(19)33850-X. doi: 10.1016/j.jtho.2019.12.109. [Epub ahead of print]

PMID:
31870883
3.

Clinical application of next-generation sequencing-based panel to BRAF wild-type advanced melanoma identifies key oncogenic alterations and therapeutic strategies.

Park C, Kim M, Kim MJ, Kim H, Ock CY, Keam B, Kim TM, Kim DW, Kim JI, Heo DS.

Mol Cancer Ther. 2019 Dec 11. pii: molcanther.0457.2019. doi: 10.1158/1535-7163.MCT-19-0457. [Epub ahead of print]

PMID:
31826932
4.

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study.

Yang JCH, Kim SW, Kim DW, Lee JS, Cho BC, Ahn JS, Lee DH, Kim TM, Goldman JW, Natale RB, Brown AP, Collins B, Chmielecki J, Vishwanathan K, Mendoza-Naranjo A, Ahn MJ.

J Clin Oncol. 2019 Dec 6:JCO1900457. doi: 10.1200/JCO.19.00457. [Epub ahead of print]

PMID:
31809241
5.

Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis.

Park C, Keam B, Yoon SH, Ock CY, Choi SM, Kim M, Park YS, Kim TM, Oh DY, Kim DW, Kim YW, Heo DS, Bang YJ.

ESMO Open. 2019 Nov 28;4(6):e000575. doi: 10.1136/esmoopen-2019-000575. eCollection 2019.

6.

Brigatinib in Crizotinib-Refractory ALK+ Non-Small Cell Lung Cancer: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.

Huber RM, Hansen KH, Paz-Ares Rodríguez L, West HL, Reckamp KL, Leighl NB, Tiseo M, Smit EF, Kim DW, Gettinger SN, Hochmair MJ, Kim SW, Langer CJ, Ahn MJ, Kim ES, Kerstein D, Groen HJM, Camidge DR.

J Thorac Oncol. 2019 Nov 19. pii: S1556-0864(19)33645-7. doi: 10.1016/j.jtho.2019.11.004. [Epub ahead of print]

7.

Asian Thoracic Oncology Research Group expert consensus statement on optimal management of stage III non-small cell lung cancer.

Tan WL, Chua KLM, Lin CC, Lee VHF, Tho LM, Chan AW, Ho GF, Reungwetwattana T, Yang JC, Kim DW, Soo RA, Chan Ahn Y, Onishi H, Ahn MJ, Mok TSK, Tan DSW, Yang F.

J Thorac Oncol. 2019 Nov 13. pii: S1556-0864(19)33640-8. doi: 10.1016/j.jtho.2019.10.022. [Epub ahead of print] Review.

PMID:
31733357
8.

Genotypic divergence of Avibacterium paragallinarum isolates with different growth requirements for nicotinamide adenine dinucleotide.

Jeong OM, Kang MS, Blackall PJ, Jeon BW, Kim JH, Jeong J, Lee HJ, Kim DW, Kwon YK, Kim JH.

Avian Pathol. 2019 Nov 27:1-8. doi: 10.1080/03079457.2019.1692128. [Epub ahead of print]

PMID:
31709803
9.

Geriatric Nutritional Risk Index as a prognostic marker in patients with extensive-stage disease small cell lung cancer: Results from a randomized controlled trial.

Lee GW, Go SI, Kim DW, Kim HG, Kim JH, An HJ, Jang JS, Kim BS, Hahn S, Heo DS.

Thorac Cancer. 2020 Jan;11(1):62-71. doi: 10.1111/1759-7714.13229. Epub 2019 Nov 10.

10.

Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer.

Ou SI, Gadgeel SM, Barlesi F, Yang JC, De Petris L, Kim DW, Govindan R, Dingemans AM, Crino L, Léna H, Popat S, Ahn JS, Dansin E, Mitry E, Müller B, Bordogna W, Balas B, Morcos PN, Shaw AT.

Lung Cancer. 2020 Jan;139:22-27. doi: 10.1016/j.lungcan.2019.10.015. Epub 2019 Oct 14.

PMID:
31706099
11.

Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitor.

Keam B, Kang CK, Jun KI, Moon SM, Suh KJ, Lee DW, Ock CY, Kim M, Choi Y, Lim Y, Lee KH, Kim SH, Kim TM, Kim TY, Oh DY, Kim DW, Im SA, Lee JS, Kim ES, Kim HB, Kim NJ, Kim YJ, Park WB, Oh MD.

Clin Infect Dis. 2019 Nov 4. pii: ciz1092. doi: 10.1093/cid/ciz1092. [Epub ahead of print]

PMID:
31680143
12.

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.

Ahn MJ, Han JY, Lee KH, Kim SW, Kim DW, Lee YG, Cho EK, Kim JH, Lee GW, Lee JS, Min YJ, Kim JS, Lee SS, Kim HR, Hong MH, Ahn JS, Sun JM, Kim HT, Lee DH, Kim S, Cho BC.

Lancet Oncol. 2019 Dec;20(12):1681-1690. doi: 10.1016/S1470-2045(19)30504-2. Epub 2019 Oct 3.

PMID:
31587882
13.

Real-world use of osimertinib in non-small cell lung cancer: ASTRIS study Korean subgroup analysis.

Cho BC, Kim DW, Park K, Lee JS, Yoo SS, Kang JH, Lee SY, Kim CH, Jang SH, Kim YC, Yoon HK, Han JY, Kim SW.

Curr Med Res Opin. 2019 Oct 4:1. doi: 10.1080/03007995.2019.1676708. [Epub ahead of print]

PMID:
31581843
14.

The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase-positive non-small cell lung cancer.

Heo JY, Park C, Keam B, Ock CY, Kim M, Kim TM, Kim DW, Kim SH, Kim YJ, Lee JS, Heo DS.

Thorac Cancer. 2019 Nov;10(11):2117-2123. doi: 10.1111/1759-7714.13195. Epub 2019 Sep 11.

15.

A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.

Kim YJ, Keam B, Ock CY, Song S, Kim M, Kim SH, Kim KH, Kim JS, Kim TM, Kim DW, Lee JS, Heo DS.

Lung Cancer. 2019 Oct;136:122-128. doi: 10.1016/j.lungcan.2019.08.031. Epub 2019 Aug 29.

PMID:
31494530
16.

Mucosa-associated lymphoid tissue lymphoma of the accessory parotid gland presenting as a simple cheek mass: A case report.

Hwang JH, Kim DW, Kim KS, Lee SY.

Medicine (Baltimore). 2019 Sep;98(36):e17042. doi: 10.1097/MD.0000000000017042.

17.

Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial.

Kim DW, Lee DH, Han JY, Lee J, Cho BC, Kang JH, Lee KH, Cho EK, Kim JS, Min YJ, Cho JY, An HJ, Kim HG, Lee KH, Kim BS, Jang IJ, Yoon S, Han O, Noh YS, Hong KY, Park K.

Lung Cancer. 2019 Sep;135:66-72. doi: 10.1016/j.lungcan.2019.07.007. Epub 2019 Jul 9.

PMID:
31447004
18.

Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.

Ahn MJ, Han JY, Kim DW, Cho BC, Kang JH, Kim SW, Yang JC, Mitsudomi T, Lee JS.

Cancer Res Treat. 2020 Jan;52(1):284-291. doi: 10.4143/crt.2019.200. Epub 2019 Jul 23.

20.

Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC.

Antonia SJ, Balmanoukian A, Brahmer J, Ou SI, Hellmann MD, Kim SW, Ahn MJ, Kim DW, Gutierrez M, Liu SV, Schöffski P, Jäger D, Jamal R, Jerusalem G, Lutzky J, Nemunaitis J, Calabrò L, Weiss J, Gadgeel S, Bhosle J, Ascierto PA, Rebelatto MC, Narwal R, Liang M, Xiao F, Antal J, Abdullah S, Angra N, Gupta AK, Khleif SN, Segal NH.

J Thorac Oncol. 2019 Oct;14(10):1794-1806. doi: 10.1016/j.jtho.2019.06.010. Epub 2019 Jun 20.

Supplemental Content

Loading ...
Support Center